Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Aug 29;2013(8):CD008908.
doi: 10.1002/14651858.CD008908.pub3.

Allogeneic stem cell transplantation versus conventional therapy for advanced primary cutaneous T-cell lymphoma

Max Schlaak  1 , Juliane Pickenhain, Sebastian Theurich, Nicole Skoetz, Michael von Bergwelt-Baildon, Peter Kurschat
Affiliations

Allogeneic stem cell transplantation versus conventional therapy for advanced primary cutaneous T-cell lymphoma

Max Schlaak et al. Cochrane Database Syst Rev. .

Abstract

Background: Primary cutaneous T-cell lymphomas (CTCL) belong to the group of non-Hodgkin lymphomas and usually run an indolent course. However, some patients progress to advanced tumour or leukaemic stages. To date, there is no cure for those cases. In the last few years, several publications reported durable responses in some patients following allogeneic stem cell transplantation (alloSCT). This is an update of a Cochrane review first published in 2011 and updated in 2013.

Objectives: To compare the efficacy and safety of conventional therapies with allogeneic stem cell transplantation in patients with advanced primary cutaneous T-cell lymphomas.

Search methods: We searched the Cochrane Central Register of Controlled Trials (CENTRAL, Issue 1), MEDLINE (1950 to January 2013), Internet-databases of ongoing trials, conference proceedings of the American Society of Clinical Oncology (ASCO, 2009 to July 2013) and the American Society of Hematology (ASH, 2009 to July 2013). We also contacted members of the European Organisation for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Task Force to check for ongoing study activities. We handsearched citations from identified trials and relevant review articles. In addition, we handsearched randomised controlled trials from the European Group for Blood and Marrow Transplantation (EBMT) and International Conference on Cutaneous T-cell Lymphoma, ASCO and ASH up to July 2013.

Selection criteria: Trials eligible for inclusion were genetically randomised controlled trials (RCTs) comparing alloSCT plus conditioning therapy (regardless of agents) with conventional therapy as treatment for advanced CTCL.

Data collection and analysis: Two review authors would have extracted data from eligible studies and assessed their quality. The primary outcome measure was overall survival; secondary outcomes were time to progression, response rate, treatment-related mortality, adverse events and quality of life.

Main results: We did not identify any randomised controlled trials from the updated search in January 2013. In 2011, we found 2077 citations but none were relevant genetically or non-genetically randomised controlled trials. All 41 studies that were thought to be potentially suitable were excluded after full text screening for being non-randomised, not including CTCL or being review articles.

Authors' conclusions: We planned to report evidence from genetically or non-genetically randomised controlled trials comparing conventional therapy and allogeneic stem cell transplantation. However, we did not identify any randomised controlled trials addressing this question. Nevertheless, prospective genetically randomised controlled trials need to be initiated to evaluate the precise role of alloSCT in advanced CTCL.

PubMed Disclaimer

Conflict of interest statement

For participation in scientific meetings Peter Kurschat was supported by Roche and Cephalon. None declared for other authors.

Figures

1
1
Update 2013
See this image and copyright information in PMC

Update of

References

References to studies excluded from this review

Alaibac 2005 {published data only}
    1. Alaibac M, Berti E, Pigozzi B, Chiarion V, Aversa S, Marino F, et al. High‐dose chemotherapy with autologous blood stem cell transplantation for aggressive subcutaneous panniculitis‐like T‐cell lymphoma. Journal of the American Academy of Dermatology 2005;52(5 Suppl 1):121‐3. [PUBMED: 15858508] - PubMed
Bertz 2002 {published data only}
    1. Bertz H, Illerhaus G, Veelken H, Finke J. Allogeneic hematopoetic stem‐cell transplantation for patients with relapsed or refractory lymphomas: comparison of high‐dose conventional conditioning versus fludarabine‐based reduced‐intensity regimens. Annals of Oncology 2002;13(1):135‐9. [PUBMED: 11863095] - PubMed
Burt 2000 {published data only}
    1. Burt RK, Guitart J, Traynor A, Link C, Rosen S, Pandolfino T, et al. Allogeneic hematopoietic stem cell transplantation for advanced mycosis fungoides: evidence of a graft‐versus‐tumor effect. Bone Marrow Transplantation 2000;25(1):111‐3. [PUBMED: 10654025] - PubMed
Chanan‐Khan 2004 {published data only}
    1. Chanan‐Khan A, Islam T, Alam A, Miller KC, Gibbs J, Barcos M, et al. Long‐term survival with allogeneic stem cell transplant and donor lymphocyte infusion following salvage therapy with anti‐CD52 monoclonal antibody (Campath) in a patient with alpha/beta hepatosplenic T‐cell non‐Hodgkin's lymphoma. Leukemia & Lymphoma 2004;45(8):1673‐5. [PUBMED: 15370223] - PubMed
Corradini 2006 {published data only}
    1. Corradini P, Tarella C, Zallio F, Dodero A, Zanni M, Valagussa P, et al. Long‐term follow‐up of patients with peripheral T‐cell lymphomas treated up‐front with high‐dose chemotherapy followed by autologous stem cell transplantation. Leukemia 2006;20(9):1533‐8. [PUBMED: 16871285] - PubMed
Cudillo 2009 {published data only}
    1. Cudillo L, Cerretti R, Baliva G, Angelis G, Postorino M, Picardi A, et al. Sézary syndrome in relapse after reduced intensity allogeneic transplant successfully treated with donor lymphocyte infusion. Bone Marrow Transplantation 2009;43(4):347‐8. [PUBMED: 18850017] - PubMed
Duarte 2008 {published data only}
    1. Duarte RF, Schmitz N, Servitje O, Sureda A. Haematopoietic stem cell transplantation for patients with primary cutaneous T‐cell lymphoma. Bone Marrow Transplantation 2008;41(7):597‐604. [PUBMED: 18176611] - PubMed
Duarte 2010 {published data only}
    1. Duarte RF, Canals C, Onida F, Gabriel IH, Arranz R, Arcese W, et al. Allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sézary syndrome: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Journal of Clinical Oncology 2010;28(29):4492‐9. [PUBMED: 20697072] - PubMed
Duvic 2010 {published data only}
    1. Duvic M, Donato M, Dabaja B, Richmond H, Singh L, Wei W, et al. Total skin electron beam and non‐myeloablative allogeneic hematopoietic stem‐cell transplantation in advanced mycosis fungoides and Sézary syndrome. Journal of Clinical Oncology 2010;28(14):2365‐72. [PUBMED: 20351328] - PubMed
Fijnheer 2003 {published data only}
    1. Fijnheer R, Sanders CJ, Canninga MR, Weger RA, Verdonck LF. Complete remission of a radiochemotherapy‐resistant cutaneous T‐cell lymphoma with allogeneic non‐myeloablative stem cell transplantation. Bone Marrow Transplantation 2003;32(3):345‐7. [PUBMED: 12858211] - PubMed
Gabriel 2007 {published data only}
    1. Gabriel IH, Olavarria E, Jones RR, Whittaker S, Chaidos A, Apperley JF. Graft versus lymphoma effect after early relapse following reduced‐intensity sibling allogeneic stem cell transplantation for relapsed cytotoxic variant of mycosis fungoides. Bone Marrow Transplantation 2007;40(4):401‐3. [PUBMED: 17589536] - PubMed
Ghobrial 2005 {published data only}
    1. Ghobrial IM, Weenig RH, Pittlekow MR, Qu G, Kurtin PJ, Ristow K, et al. Clinical outcome of patients with subcutaneous panniculitis‐like T‐cell lymphoma. Leukemia & Lymphoma 2005;46(5):703‐8. [PUBMED: 16019507] - PubMed
Guitart 2002 {published data only}
    1. Guitart J, Wickless SC, Oyama Y, Kuzel TM, Rosen ST, Traynor A, et al. Long‐term remission after allogeneic hematopoietic stem cell transplantation for refractory cutaneous T‐cell lymphoma. Archives of Dermatology 2002;138(10):1359‐65. [PUBMED: 12374543] - PubMed
Hamadani 2008 {published data only}
    1. Hamadani M, Awan FT, Elder P, Lin TS, Porcu P, Blum KA, et al. Allogeneic hematopoietic stem cell transplantation for peripheral T cell lymphomas; evidence of graft‐versus‐T cell lymphoma effect. Biology of Blood & Marrow Transplantation 2008;14(4):480‐3. [PUBMED: 18342792] - PubMed
Hathaway 2007 {published data only}
    1. Hathaway T, Subtil A, Kuo P, Foss F. Efficacy of denileukin diftitox in subcutaneous panniculitis‐like T‐cell lymphoma. Clinical Lymphoma & Myeloma 2007;7(8):541‐5. [PUBMED: 18021473] - PubMed
Herbert 2004 {published data only}
    1. Herbert KE, Spencer A, Grigg A, Ryan G, McCormack C, Prince HM. Graft‐versus‐lymphoma effect in refractory cutaneous T‐cell lymphoma after reduced‐intensity HLA‐matched sibling allogeneic stem cell transplantation. Bone Marrow Transplantation 2004;34(6):521‐5. [PUBMED: 15286686] - PubMed
Hoff 2008 {published data only}
    1. Hoff NP, Groffik A, Mota R, Pippirs U, Hengge UR, Kobbe G, et al. Successful use of allogeneic stem cell transplantation for treatment‐refractory mycosis fungoides [Erfolgreicher Einsatz einer allogenen Stammzelltransplantation bei therapierefraktärer Mycosis fungoides]. Hautarzt 2008;59(10):779‐82. [PUBMED: 18773178] - PubMed
Horwitz 2008 {published data only}
    1. Horwitz SM, Olsen EA, Duvic M, Porcu P, Kim YH. Review of the treatment of mycosis fungoides and Sézary syndrome: a stage‐based approach. Journal of the National Comprehensive Cancer Network 2008;6(4):436‐42. [PUBMED: 18433609] - PubMed
Ichii 2006 {published data only}
    1. Ichii M, Hatanaka K, Imakita M, Ueda Y, Kishino B, Tamaki T. Successful treatment of refractory subcutaneous panniculitis‐like T‐cell lymphoma with allogeneic peripheral blood stem cell transplantation from HLA‐mismatched sibling donor. Leukemia & Lymphoma 2006;47(10):2250‐2. [PUBMED: 17071503] - PubMed
Kahata 2008 {published data only}
    1. Kahata K, Hashino S, Takahata M, Fujisawa F, Kondo T, Kobayashi S, et al. Durable remission of Sézary syndrome after unrelated bone marrow transplantation by reduced‐intensity conditioning. Acta Haematologica 2008;120(1):14‐8. [PUBMED: 18716396] - PubMed
Knobler 2001 {published data only}
    1. Knobler R, Girardi M. Extracorporeal photochemoimmunotherapy in cutaneous T cell lymphomas. Annals of the New York Academy of Sciences 2001;941:123‐38. [PUBMED: 11594566] - PubMed
Knobler 2002 {published data only}
    1. Knobler E, Warmuth I. Extracorporeal photochemotherapy: a case report and update. Cutis 2002;69(2):119‐23. [PUBMED: 11868976] - PubMed
Koch 2009 {published data only}
    1. Koch R, Jaffe ES, Mensing C, Zeis M, Schmitz N, Sander CA. Cutaneous gamma/delta T‐cell lymphoma [Primär kutanes Gamma/Delta‐T‐Zell‐Lymphom]. Journal der Deutschen Dermatologischen Gesellschaft 2009;7(12):1065‐7. [PUBMED: 19694889] - PMC - PubMed
Majhail 2005 {published data only}
    1. Majhail NS, Burns LJ. Hematopoietic stem cell transplantation in the treatment of peripheral T‐cell lymphomas. Current Hematology Reports 2005;4(4):252‐9. [PUBMED: 16009039] - PubMed
Masood 2002 {published data only}
    1. Masood N, Russell KJ, Olerud JE, Sabath DE, Sale GE, Doney KC, et al. Induction of complete remission of advanced stage mycosis fungoides by allogeneic hematopoietic stem cell transplantation. Journal of the American Academy of Dermatology 2002;47(1):140‐5. [PUBMED: 12077596] - PubMed
Molina 1999 {published data only}
    1. Molina A, Nademanee A, Arber DA, Forman SJ. Remission of refractory Sézary syndrome after bone marrow transplantation from a matched unrelated donor. Biology of Blood & Marrow Transplantation 1999;5(6):400‐4. [PUBMED: 10595818] - PubMed
Molina 2005 {published data only}
    1. Molina A, Zain J, Arber DA, Angelopolou M, O'Donnell M, Murata‐Collins J, et al. Durable clinical, cytogenetic and molecular remissions after allogeneic hematopoietic cell transplantation for refractory Sézary syndrome and mycosis fungoides. Journal of Clinical Oncology 2005;23(25):6163‐71. [PUBMED: 16135483] - PubMed
Mukai 2003 {published data only}
    1. Mukai HY, Okoshi Y, Shimizu S, Katsura Y, Takei N, Hasegawa Y, et al. Successful treatment of a patient with subcutaneous panniculitis‐like T‐cell lymphoma with high‐dose chemotherapy and total body irradiation. European Journal of Haematology 2003;70(6):413‐6. [PUBMED: 12756026] - PubMed
Nakahashi 2009 {published data only}
    1. Nakahashi H, Tsukamoto N, Yamane A, Saitoh T, Uchiumi H, Handa H, et al. Autologous peripheral blood stem cell transplantation to treat CHOP‐refractory aggressive subcutaneous panniculitis‐like T cell lymphoma. Acta Haematologica 2009;121(4):239‐42. [PUBMED: 19556752] - PubMed
Nishio 2000 {published data only}
    1. Nishio M, Koizumi K, Endo T, Takashima H, Haseyama Y, Fujimoto K, et al. Effective high‐dose chemotherapy combined with CD34+‐selected autologous peripheral blood stem cell transplantation in a patient with cutaneous CD30‐negative large T cell lymphoma. Bone Marrow Transplantation 2000;25(12):1315‐7. [PUBMED: 10871740] - PubMed
Okada 2010 {published data only}
    1. Okada S, Nannya Y, Ota S, Takazawa Y, Yamamoto G, Kumano K, et al. Cutaneous T‐cell lymphoma (mycosis fungoides) relapsed with different immunological phenotype after bone marrow transplant. British Journal of Dermatology 2010;162(1):229‐30. [PUBMED: 19903173] - PubMed
Perez‐Persona 2006 {published data only}
    1. Perez‐Persona E, Mateos‐Mazon JJ, Lopez‐Villar O, Arcos MJ, Encinas C, Graciani IF, et al. Complete remission of subcutaneous panniculitic T‐cell lymphoma after allogeneic transplantation. Bone Marrow Transplantation 2006;38(12):821‐2. [PUBMED: 17057727] - PubMed
Poligone 2010 {published data only}
    1. Poligone B, Heald P. Innovative therapy of cutaneous T‐cell lymphoma: beyond psoralen and ultraviolet light and nitrogen mustard. Dermatologic Clinics 2010;28(3):501‐10. [PUBMED: 20510760] - PMC - PubMed
Rook 1994 {published data only}
    1. Rook AH, Wolfe JT. Role of extracorporeal photopheresis in the treatment of cutaneous T‐cell lymphoma, autoimmune disease, and allograft rejection. Journal of Clinical Apheresis 1994;9(1):28‐30. [PUBMED: 8195109] - PubMed
Russell‐Jones 2001 {published data only}
    1. Russell‐Jones R, Child F, Olavarria E, Whittaker S, Spittle M, Apperley J. Autologous peripheral blood stem cell transplantation in tumor‐stage mycosis fungoides: predictors of disease‐free survival. Annals of the New York Academy of Sciences 2001;941:147‐54. [PUBMED: 11594568] - PubMed
Shustov 2010 {published data only}
    1. Shustov AR, Gooley TA, Sandmaier BM, Shizuru J, Sorror ML, Sahebi F, et al. Allogeneic haematopoietic cell transplantation after nonmyeloablative conditioning in patients with T‐cell and natural killer‐cell lymphomas. British Journal of Haematology 2010;150(2):170‐8. [PUBMED: 20507311] - PMC - PubMed
Soligo 2003 {published data only}
    1. Soligo D, Ibatici A, Berti E, Morandi P, Longhi E, Venegoni L, et al. Treatment of advanced mycosis fungoides by allogeneic stem‐cell transplantation with a nonmyeloablative regimen. Bone Marrow Transplantation 2003;31(8):663‐6. [PUBMED: 12692606] - PubMed
Taylor 1992 {published data only}
    1. Taylor A, Gasparro FP. Extracorporeal photochemotherapy for cutaneous T‐cell lymphoma and other diseases. Seminars in Hematology 1992;29(2):132‐41. [PUBMED: 1594945] - PubMed
Tsuji 2010 {published data only}
    1. Tsuji H, Wada T, Murakami M, Kashiwagi T, Ito Y, Ishida‐Yamamoto A, et al. Two cases of mycosis fungoides treated by reduced‐intensity cord blood transplantation. Journal of Dermatology 2010;37(12):1040‐5. [PUBMED: 21083707] - PubMed
Wu 2009 {published data only}
    1. Wu PA, Kim YH, Lavori PW, Hoppe RT, Stockerl‐Goldstein KE. A meta‐analysis of patients receiving allogeneic or autologous hematopoietic stem cell transplant in mycosis fungoides and Sézary syndrome. Biology of Blood & Marrow Transplantation 2009;15(8):982‐90. [PUBMED: 19589488] - PMC - PubMed
Zain 2010 {published data only}
    1. Zain J, Kaminetzky D, O'Connor OA. Emerging role of epigenetic therapies in cutaneous T‐cell lymphomas. Expert Review of Hematology 2010;3(2):187‐203. [PUBMED: 21083462] - PubMed

Additional references

Aoudjhane 2005
    1. Aoudjhane M, Labopin M, Gorin NC, Shimoni A, Ruutu T, Kolb HJ, et al. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT). Leukemia 2005;19(12):2304‐12. [PUBMED: 16193083] - PubMed
Apisarnthanarax 2002
    1. Apisarnthanarax N, Talpur R, Duvic M. Treatment of cutaneous T cell lymphoma: current status and future directions. American Journal of Clinical Dermatology 2002;3(3):193‐215. [PUBMED: 11978140] - PubMed
Dearden 2007
    1. Dearden C. Is there a role for hemopoietic stem‐cell transplantation in CTCL?. Oncology (Williston Park, N.Y.) 2007;21(2 Suppl 1):24‐8. [PUBMED: 17474356] - PubMed
Deeks 2011
    1. Deeks JJ, Higgins JPT, Altman DG. Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Egger 1997
    1. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta‐analysis detected by a simple, graphical test. BMJ 1997;315(7109):629‐34. - PMC - PubMed
Feinstein 2001
    1. Feinstein L, Storb R. Nonmyeloablative hematopoietic cell transplantation. Current Opinion in Oncology 2001;13(2):95‐100. [MEDLINE: ] - PubMed
Foss 2004
    1. Miller KB, Roberts TF, Chan G, Schenkein DP, Lawrence D, Sprague K, et al. A novel reduced intensity regimen for allogeneic hematopoietic stem cell transplantation associated with a reduced incidence of graft‐versus‐host disease. Bone Marrow Transplant 2004;33(9):881‐9. [PUBMED: 14990986] - PubMed
Gardner 2009
    1. Gardner JM, Evans KG, Musiek A, Rook AH, Kim EJ. Update on treatment of cutaneous T‐cell lymphoma. Current Opinion in Oncology 2009;21(2):131‐7. [PUBMED: 19532014] - PubMed
Giralt 2001
    1. Giralt S, Thall PF, Khouri I, Wang X, Braunschweig I, Ippolitti C, et al. Melphalan and purine analog‐containing preparative regimens: reduced‐intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 2001;97(3):631‐7. [PUBMED: 11157478] - PubMed
Higgins 2011a
    1. Higgins JPT, Deeks JJ, Altman DG. Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Higgins 2011b
    1. Higgins JPT, Altman DG. Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Higgins 2011c
    1. Higgins JPT, Deeks JJ. Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Hoff 2010
    1. Hoff NP, Bruch‐Gerharz D. The role of hematopoietic stem‐cell transplantation in cutaneous T‐cell lymphoma. Giornale Italiano di Dermatologia e Venereologia 2010;145(3):345‐59. [PUBMED: 20461043] - PubMed
Introcaso 2008
    1. Introcaso CE, Leber B, Greene K, Ubriani R, Rook AH, Kim EJ. Stem cell transplantation in advanced cutaneous T‐cell lymphoma. Journal of the American Academy of Dermatology 2008;58(4):645‐9. [PUBMED: 18258335] - PubMed
Karanes 2008
    1. Karanes C, Nelson GO, Chitphakdithai P, Agura E, Ballen KK, Bolan CD, et al. Twenty years of unrelated donor hematopoietic cell transplantation for adult recipients facilitated by the National Marrow Donor Program. Biology of Blood and Marrow Transplantation 2008;14(9 Suppl):8‐15. [PUBMED: 18721775] - PubMed
Kim 2003
    1. Kim YH, Liu HL, Mraz‐Gernhard S, Varghese A, Hoppe RT. Long‐term outcome of 525 patients with mycosis fungoides and Sézary syndrome: clinical prognostic factors and risk for disease progression. Archives of Dermatology 2003;139(7):857‐66. [PUBMED: 12873880] - PubMed
Knobler 2004
    1. Knobler E. Current management strategies for cutaneous T‐cell lymphoma. Clinics in Dermatology 2004;22(3):197‐208. [PUBMED: 15262305] - PubMed
Koeppel 1994
    1. Koeppel MC, Stoppa AM, Resbeut M, Blaise D, Coignet M, Coulier L, et al. Mycosis fungoides and allogenic bone marrow transplantation. Acta Dermato‐Venereologica 1994;74(4):331‐2. [PUBMED: 7976105] - PubMed
Kolb 1998
    1. Kolb HJ. Donor leukocyte transfusions for treatment of leukemic relapse after bone marrow transplantation. EBMT Immunology and Chronic Leukemia Working Parties. Vox Sanguinis 1998;74(Suppl 2):321‐9. [PUBMED: 9704463] - PubMed
Kolb 2008
    1. Kolb HJ. Graft‐versus‐leukemia effects of transplantation and donor lymphocytes. Blood 2008;112(12):4371‐83. [PUBMED: 19029455] - PubMed
Lansigan 2010
    1. Lansigan F, Foss FM. Current and emerging treatment strategies for cutaneous T‐cell lymphoma. Drugs 2010;70(3):273‐86. [PUBMED: 20166766] - PubMed
Lau 2006
    1. Lau J, Ioannidis JP, Terrin N, Schmid CH, Olkin I. The case of the misleading funnel plot. BMJ 2006;333(7568):597‐600. - PMC - PubMed
Lefebvre 2011
    1. Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Ljungman 2010
    1. Ljungman P, Bregni M, Brune M, Cornelissen J, Witte T, Dini G, et al. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009. Bone Marrow Transplantation 2010;45(2):219‐34. [PUBMED: 19584824] - PubMed
Parmar 1998
    1. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta‐analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17(24):2815‐34. - PubMed
RevMan [Computer program]
    1. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.0. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2008.
Ringdén 2009
    1. Ringdén O, Karlsson H, Olsson R, Omazic B, Uhlin M. The allogeneic graft‐versus‐cancer effect. British Journal of Haematology 2009;147(5):614‐33. [PUBMED: 19735262] - PubMed
Rocha 2009
    1. Rocha V, Mohty M, Gluckman E, Rio B, Eurocord, Reduced‐Intensity Conditioning Subcommittee of the Acute Leukaemia Working Party, French Society of Bone Marrow Transplantation and Cellular Therapy. Reduced‐intensity conditioning regimens before unrelated cord blood transplantation in adults with acute leukaemia and other haematological malignancies. Current Opinion in Oncology 2009;21(Suppl 1):31‐4. [PUBMED: 19561411] - PubMed
Roddie 2011
    1. Roddie C, Peggs KS. Donor lymphocyte infusion following allogeneic hematopoietic stem cell transplantation. Expert Opinion on Biological Therapy 2011;11(4):473‐87. [PUBMED: 21269237] - PubMed
Saunes 2009
    1. Saunes M, Nilsen TI, Johannesen TB. Incidence of primary cutaneous T‐cell lymphoma in Norway. The British Journal of Dermatology 2009;160(2):376‐9. [PUBMED: 18808419] - PubMed
Stadler 2008
    1. Stadler R, Assaf C, Klemke CD, Nashan D, Weichenthal M, Dummer R, et al. Short German guidelines: cutaneous lymphomas. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG 2008;6 Suppl 1:S25‐31. [PUBMED: 18801140] - PubMed
Stang 2006
    1. Stang A, Streller B, Katalinic A, Lehnert M, Eisinger B, Kaatsch P, et al. Incidence of skin lymphoma in Germany. Annals of Epidemiology 2006;16(3):214‐22. [PUBMED: 16019225] - PubMed
Sterne 2008
    1. Sterne JAC, Egger M, Moher D. Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 [updated September 2008]. The Cochrane Collaboration, 2008. Available from www.cochrane‐handbook.org.
Storb 2009
    1. Storb R. Reduced‐intensity conditioning transplantation in myeloid malignancies. Current Opinion in Oncology 2009;21(Suppl 1):3‐5. [PUBMED: 19561410] - PMC - PubMed
Tierney 2007
    1. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time‐to‐event data into meta‐analysis. Trials 2007;8:16. - PMC - PubMed
Vidulich 2009
    1. Vidulich KA, Talpur R, Bassett RL, Duvic M. Overall survival in erythrodermic cutaneous T‐cell lymphoma: an analysis of prognostic factors in a cohort of patients with erythrodermic cutaneous T‐cell lymphoma. International Journal of Dermatology 2009;48(3):243‐52. [PUBMED: 19261011] - PubMed
Wheatley 2004
    1. Wheatley K, Gray R. Commentary: Mendelian randomization‐‐an update on its use to evaluate allogeneic stem cell transplantation in leukaemia. International Journal of Epidemiology 2004;33(1):15‐7. [PUBMED: 15075139] - PubMed
Whittaker 2003
    1. Whittaker SJ, Marsden JR, Spittle M, Russell Jones R. Joint British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous T‐cell lymphomas. The British Journal of Dermatology 2003;149(6):1095‐107. [PUBMED: 14696593] - PubMed
Whittaker 2007
    1. Whittaker SJ, Foss FM. Efficacy and tolerability of currently available therapies for the mycosis fungoides and Sézary syndrome variants of cutaneous T‐cell lymphoma. Cancer Treatment Reviews 2007;33(2):146‐60. [PUBMED: 17275192] - PubMed

Publication types

MeSH terms